Debt & Credit Markets

GFL Environmental is using sophisticated financial tools to fund a massive acquisition. We explore how this move reshapes the industry and signals a new era of growth.

Vivos Therapeutics gets more time from its lender to raise capital, a crucial move as it navigates Nasdaq compliance issues and funds a major business overhaul.

Upexi's debt-for-equity deal shores up its balance sheet but raises questions about dilution and the high-risk strategy behind its massive Solana treasury.

Amid market volatility, Canyon Partners' latest €400M CLO showcases strategic precision. We deconstruct the deal and what it signals for European credit.

Claranova's sudden CFO change comes at a pivotal moment. We analyze the move's impact on its debt strategy and its pivot to a pure-play SaaS model.

Clip Money extends its debt runway, but a split among investors reveals a deeper story. Is this a savvy move to fuel expansion or a necessary patch on a leaky hull?

The fast-food giant is refinancing its debt at a much higher interest rate. Is this a savvy move to optimize its balance sheet or a costly sign of trouble?

AM Best's 'a-' rating on Ameriprise's new notes isn't just a grade; it's a testament to strategic foresight and a beacon for investors.

The maker of Crisco and Cream of Wheat extends its debt maturity to 2031, but at a staggering 11% rate, revealing the harsh realities of today's credit markets.

Crescent's largest-ever fund close highlights booming investor appetite for private credit and promises a major capital infusion for the U.S. lower middle market.

The new fund from Loomis Sayles and Natixis enters the booming interval fund market, offering access to private credit amid growing regulatory scrutiny.

Facing default, the Brazilian mall operator offers a risky swap of distressed bonds for fund shares, forcing a tough choice on international investors.

A $290M war chest fuels a new public biotech aiming to help millions of migraine patients who don't respond to current blockbuster therapies.

Baxter is buying back billions in debt, a strategic move to clean its balance sheet. But with operational issues mounting, is it enough to win back investors?